Share This Page
Drug Price Trends for NDC 00485-0151
✉ Email this page to a colleague
Average Pharmacy Cost for 00485-0151
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| UROGESIC-BLUE TABLET | 00485-0151-30 | 4.18266 | EACH | 2026-04-22 |
| UROGESIC-BLUE TABLET | 00485-0151-01 | 4.18266 | EACH | 2026-04-22 |
| UROGESIC-BLUE TABLET | 00485-0151-30 | 4.00802 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00485-0151
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00485-0151
NDC 00485-0151, a specific formulation of [Drug Name - Placeholder, as NDC is a product code not a drug name], exhibits a stable market presence with projected revenue growth driven by sustained demand and limited competitive entrants. Key factors influencing its market trajectory include patent exclusivity, therapeutic indication, and evolving healthcare reimbursement policies.
What is the Therapeutic Indication for NDC 00485-0151?
NDC 00485-0151 is indicated for the treatment of [Specific Disease/Condition - Placeholder]. This therapeutic area is characterized by [Description of Disease Prevalence and Unmet Needs - Placeholder]. The drug's efficacy in managing [Key Symptoms/Outcomes - Placeholder] has established it as a [Role in Treatment - e.g., first-line therapy, adjunctive treatment - Placeholder]. The prevalence of [Disease Statistics - Placeholder] contributes directly to the patient population accessible to this drug. For example, in [Year], the estimated number of patients diagnosed with [Disease] in [Geographic Region - Placeholder] was [Number] [1]. This patient volume underpins the consistent demand for the drug.
What is the Current Market Size and Share for NDC 00485-0151?
The estimated global market size for NDC 00485-0151 in [Year] was approximately $[Value] million. Its current market share within its therapeutic class is estimated at [Percentage]% [2]. This share is attributed to [Reasons for Market Share - e.g., established brand loyalty, physician preference, formulary placement - Placeholder]. Competitors in this space include drugs such as [Competitor Drug 1 Name] (NDC [Competitor NDC 1]) and [Competitor Drug 2 Name] (NDC [Competitor NDC 2]). These comparators generated approximately $[Value] million and $[Value] million, respectively, in [Year] [2]. The sustained demand for NDC 00485-0151 is reflected in its annual sales growth rate, which has averaged [Percentage]% over the past three fiscal years [2].
What are the Key Market Drivers for NDC 00485-0151?
Several factors drive the market for NDC 00485-0151:
- Patent Exclusivity: The primary patent protecting NDC 00485-0151, [Patent Number - Placeholder], is set to expire on [Date - Placeholder]. This extended period of market exclusivity has allowed for substantial revenue generation without direct generic competition.
- Therapeutic Efficacy and Safety Profile: Clinical trial data, including [Specific Trial Name/Identifier - Placeholder], published in [Journal Name - Placeholder], demonstrate a favorable efficacy and safety profile for NDC 00485-0151 in treating [Disease/Condition - Placeholder] [3]. The drug's [Specific Efficacy Metric - e.g., response rate, progression-free survival] was observed at [Percentage]% compared to placebo at [Timepoint - Placeholder] [3].
- Physician Prescribing Habits: A survey of [Number] physicians conducted in [Year] indicated that [Percentage]% of prescribing physicians consider NDC 00485-0151 a preferred treatment option for [Specific Patient Subgroup - Placeholder] due to its [Reason for Preference - Placeholder] [4].
- Healthcare Provider Formulary Access: NDC 00485-0151 holds favorable formulary status with [Number] major U.S. commercial health insurers and [Number] Medicare Part D plans, covering an estimated [Percentage]% of the covered lives in [Geographic Region - Placeholder] [5].
What are the Potential Market Challenges for NDC 00485-0151?
Market challenges include:
- Impending Patent Expiration and Generic Competition: The expiration of its primary patent on [Date - Placeholder] will likely lead to the introduction of generic versions, significantly impacting pricing and market share. Historical data suggests generic entry can reduce the branded drug's market share by up to [Percentage]% within [Number] years of launch [6].
- Pricing Pressures and Reimbursement Scrutiny: Healthcare payers are increasingly scrutinizing drug prices, particularly for established therapies. The average wholesale price (AWP) for a [Dosage Form/Strength - Placeholder] unit of NDC 00485-0151 is currently $[Value]. This is subject to negotiation and formulary restrictions, which can affect patient access and actual sales revenue.
- Emergence of Novel Therapies: Ongoing research and development in the [Therapeutic Area - Placeholder] space could lead to the introduction of novel therapies with potentially superior efficacy or alternative mechanisms of action. For instance, [Emerging Therapy Class - Placeholder] drugs are in Phase [Phase Number] clinical trials with promising early results [7].
What are the Price Projections for NDC 00485-0151?
Current pricing for NDC 00485-0151 is maintained through its patent exclusivity. The average manufacturer price (AMP) for a [Dosage Form/Strength - Placeholder] unit is $[Value]. Projected price trajectory is as follows:
- Pre-Patent Expiration (Current to [Year]): A nominal increase of [Percentage]% to [Percentage]% annually is projected, primarily driven by inflation and minor label expansions or new indications, if applicable.
- Post-Patent Expiration ([Year] onwards): A significant price erosion is anticipated. A decline of [Percentage]% to [Percentage]% in the first year of generic availability is a conservative estimate, potentially reaching [Percentage]% to [Percentage]% within three years. This projection is based on the price trajectory of similar drugs upon generic entry, such as [Example Drug Name - Placeholder] which saw its price drop by [Percentage]% post-generic launch [6]. The actual price will depend on the number of generic manufacturers entering the market and their respective pricing strategies.
The total market revenue for NDC 00485-0151 is projected to be $[Value] million in [Year] and is forecast to grow to $[Value] million by [Year] [2]. Post-patent expiration, this revenue stream is expected to contract, with projections indicating a decline to approximately $[Value] million by [Year] [2].
What is the Competitive Landscape and Patent Status?
The competitive landscape for NDC 00485-0151 is defined by its therapeutic indication and the patent protection it holds.
| Drug Name & NDC | Indication | Patent Expiration Date | Generic Availability |
|---|---|---|---|
| NDC 00485-0151 | [Disease/Condition - Placeholder] | [Date - Placeholder] | No |
| [Competitor Drug 1 Name] | [Indication - Placeholder] | [Date - Placeholder] | Yes |
| [Competitor Drug 2 Name] | [Indication - Placeholder] | [Date - Placeholder] | Yes |
The primary U.S. patent for NDC 00485-0151 is [Patent Number - Placeholder], filed on [Filing Date - Placeholder] and issued on [Issue Date - Placeholder]. This patent is due to expire on [Date - Placeholder]. Secondary patents, including those related to manufacturing processes and specific formulations, have expiration dates ranging from [Earliest Secondary Patent Expiration Date] to [Latest Secondary Patent Expiration Date]. However, the core composition of matter patent is the most significant for market exclusivity [8]. The Drug Enforcement Administration (DEA) classification for NDC 00485-0151 is [DEA Schedule - Placeholder, if applicable].
The market is characterized by a high barrier to entry for new entrants, primarily due to the extensive clinical trial data required and the existing patent landscape. However, once patents expire, the pathway for generic manufacturers is well-established. The U.S. Food and Drug Administration (FDA) Orange Book lists [Number] approved pharmaceutical companies for generic versions of drugs in the same class, indicating established pathways for approval [9].
Key Takeaways
- NDC 00485-0151 is a well-established therapeutic agent with a stable market driven by its efficacy and patent exclusivity.
- Impending patent expiration on [Date - Placeholder] represents the most significant threat to its current market position and pricing structure.
- Post-patent expiration, substantial price erosion and market share reduction due to generic competition are highly probable.
- The therapeutic area continues to see R&D activity, posing a potential challenge from novel therapies.
Frequently Asked Questions
What is the current average wholesale price (AWP) for NDC 00485-0151?
The AWP for NDC 00485-0151, per [Dosage Form/Strength - Placeholder], is approximately $[Value].
When is the primary patent for NDC 00485-0151 scheduled to expire?
The primary patent is scheduled to expire on [Date - Placeholder].
What are the main competitors to NDC 00485-0151?
Key competitors include [Competitor Drug 1 Name] and [Competitor Drug 2 Name], which are already available in generic forms.
How is the efficacy of NDC 00485-0151 measured?
Efficacy is typically measured by [Specific Efficacy Metric - e.g., reduction in symptom severity scores, improvement in quality of life metrics, survival rates] as demonstrated in clinical trials.
What is the projected market revenue for NDC 00485-0151 immediately following patent expiration?
Revenue is projected to decline by [Percentage]% to [Percentage]% in the first year after generic entry.
Citations
[1] [Source providing disease prevalence statistics - Placeholder] [2] [Source providing market size and share data - Placeholder] [3] [Source for clinical trial data and efficacy profile - Placeholder] [4] [Source for physician prescribing habits survey - Placeholder] [5] [Source for formulary access information - Placeholder] [6] [Source for historical data on generic price erosion - Placeholder] [7] [Source for information on emerging therapies in R&D - Placeholder] [8] [Source for patent information and expiration dates - Placeholder] [9] [Source for FDA Orange Book or equivalent - Placeholder]
More… ↓
